• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
HMO
Click for more information
0.00% 6.8¢

HEARMEOUT LIMITED

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
HMO
Ann: Appendix 4G 		01/03/19 0 88
01/03/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  88 
HMO
Ann: Appendix 4E & Annual Financial Statements 		01/03/19 0 197
01/03/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  197 
HMO
Ann: Appointment of Executive Director 		25/02/19 0 135
25/02/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  135 
HMO
Ann: Appendix 4C - quarterly 		31/01/19 0 199
31/01/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  199 
HMO
News: HMO Hearmeout Enters Exclusive Commercial Agreement With Indian Business Avidsys Infotec 		09/01/19 2 466
09/01/19 Last post  sammysheart Comments Created with Sketch.  2  Views Created with Sketch.  466 
HMO
Ann: License agreement to grow HMO platform in India and Asia 		10/12/18 0 154
10/12/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  154 
HMO
Ann: Appendix 3B-Release from escrow & cancellation of options 		06/12/18 0 168
06/12/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  168 
HMO
Ann: Appendix 4C - quarterly 		04/12/18 4 1.4K
04/12/18 Last post  skeeno Comments Created with Sketch.  4  Views Created with Sketch.  1.4K 

See All Discussions arrow Created with Sketch.

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Cyclone signs MOU with Vale for development of Iron Bear play Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.